Adults diagnosed with narcolepsy type 2 or idiopathic hypersomnia (IH)

Narcolepsy related words printed on white background.
$2,750
Newark, NJ
Male & Female
18-65
Non-Smokers
10 night(s)
1 outpatient visit(s)
Screening starts on: November 20, 2023

You may qualify and be compensated up to $2,750 for participating in this study if you meet the following criteria:

  • Males and females 18-65 years old
  • Diagnosed with narcolepsy type 2 (without cataplexy) or with idiopathic hypersomnia (IH)
  • BMI between 18 and 45 (use the BMI calculator below)
  • Non-smokers
  • Additional criteria apply

Transportation and other means of support will be provided throughout the study periods.

Study design and check-in dates: upon participants’ availability; see here.

To participate, contact Mrs. Luz Stevens at 973-388-8448 or luz.stevens@biotrial.com

Refer a friend: Earn up to $500 if your friend is eligible and participates in this study.

Study objective: Provide preliminary data regarding initial clinical proof of concept, tolerability, and safety of the investigational study drug ALKS2680 in the narcolepsy type 2 (narcolepsy without cataplexy) and idiopathic hypersomnia (IH) patient populations.

What is narcolepsy? Narcolepsy is a sleep disorder that makes people very drowsy during the day. They find it hard to stay awake for long periods, fall asleep suddenly, and may have hallucinations.

Find a trial

Explore other paid clinical trials

Our clinical trials cover a broad range of therapeutic areas. Browse our featured trials to find one that matches your profile or click to view all available studies.